drugset / Trial / NCT00413582
Pain Management for Pectus Excavatum Repair
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to scientifically evaluate two different management strategies for post-operative pain after pectus excavatum repair. The hypothesis is that pain management without an epidural decreases hospital stay without compromising comfort. The primary outcome variable is length of hospitalization after the intervention.
Timeline
- Start
- 2006-10
- Primary completion
- 2010-05
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clonidine | Other / unclassified | 1.5 ug/ml | Other |
| Comparator | Clonidine | Other / unclassified | 1.8 ug/kg | Other |
| Comparator | Clonidine | Other / unclassified | 2 ug/kg | Other |
| Comparator | Clonidine | Other / unclassified | 0.1 mg | Other |
| Comparator | Fentanyl | Other / unclassified | 0.5 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 1 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 1.2 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 2 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 2 ug/ml | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 3 ug/kg | Intravenous |
| Comparator | Fentanyl | Other / unclassified | 6 ug/kg | Intravenous |
| Subject | Hydromorphone | Other / unclassified | 5 ug/kg | Intravenous |
| Subject | Hydromorphone | Other / unclassified | 6 ug/kg | Intravenous |
| Subject | Hydromorphone | Other / unclassified | 8 ug/kg | Intravenous |
| Comparator | Ropivacaine | Other / unclassified | 0.1 % | Other |
| Comparator | Midazolam | Small molecule | 0.025 mg/kg | Intravenous |
| Comparator | Midazolam | Small molecule | 0.05 mg/kg | Intravenous |
Indications
No indication recorded.